The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4 + and CD8 + T cells that expressed the inflammatory cytokine IFN-g. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3 + Tregs. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8 + T cells and IFNg. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer.
Introduction
While the immune system has a powerful ability to recognize and kill cancer cells, its function is often suppressed, preventing clearance of disease. A variety of innate and adaptive immune lineages causes immunosuppression within tumors, including immature DCs, plasmacytoid DCs, myeloid-derived suppressor cells, CD4 +
Foxp3
+ Tregs, IL-10-secreting type-I Tregs, and CD1d-restricted natural killer T cells (1) (2) (3) (4) (5) . Thus, a relatively well-characterized network of innate and adaptive immunosuppressive cell types drives immunosuppression, but molecular mechanisms required for the development of immunosuppressive responses within tumors are poorly elucidated. TFs play key roles in cellular differentiation and bind to regulatory DNA to control gene expression. BACH2 is a 92-kDa transcription factor (TF) of the basic leucine zipper family and functions within multiple innate and adaptive lineages to control immune function. In B cells, BACH2 is critical for somatic hypermutation and class-switch recombination, and its absence leads to impaired formation of class-switched antibody responses (6, 7) . In CD4 + T cells, BACH2 promotes the development of Foxp3 + Tregs by suppressing effector cell transcriptional programs (8, 9) . BACH2 is also required for normal development and function of alveolar macrophages (10) . Consistent with its role in regulating the development and function of diverse immune cell types, the BACH2 gene in humans is a prominent susceptibility locus for multiple autoimmune and allergic diseases (11) (12) (13) (14) . Thus, BACH2 functions in a variety of cellular lineages that can either promote or suppress immune responses against tumors. However, its function in controlling tumor immunity has not been elucidated. In this study, we have found that BACH2 is required to establish immunosuppression within tumors. We found that growth of B16 melanoma and EL-4 lymphoma tumors was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon adaptive immunity. Analysis of tumor-infiltrating lymphocytes in Bach2-deficient mice revealed high frequencies of rapidly proliferating CD4 + and CD8 + effector cells expressing the inflammatory cytokine IFN-γ. Lymphocyte activation coincided with reduction in the frequency of intratumoral CD4 + Foxp3 + Tregs. Treg-dependent inhibition of intratumoral CD8 + T cells and IFN-γ was required for BACH2-mediated tumor immunosuppression. These findings identify BACH2 as a key component of the molecular program of tumor immunosuppression and identify a target for therapies aimed at reversing immunosuppression in cancer.
Results and Discussion
BACH2 promotes tumor immunosuppression. To determine the function of BACH2 in regulating tumor immunity, we implanted syngeneic B16 melanoma cells subcutaneously into littermate
The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4 + and CD8 + T cells that expressed the inflammatory cytokine IFN-γ. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3 cient animals were uniformly distinct from those of WT animals ( Figure 1C ). Analysis of transcriptional profiles for global differences in gene expression identified 3,623 differentially expressed transcripts (Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/JCI82884DS1), which enabled tumors to be distinguished based upon hierarchical cluster analysis ( Figure 1D ). Gene set enrichment analysis (15) indicated induction of transcriptional signatures of both innate and WT or Bach2-deficient mice and measured tumor size at serial time points following implantation. Strikingly, we noted reduced growth of B16 tumors in Bach2-deficient animals ( Figure 1A ). Similar observations were made using the EL-4 lymphoma model ( Figure 1B ). To determine the basis for impaired tumor growth in Bach2-deficient animals, we performed whole-tumor transcriptional profiling of B16 tumors from WT and Bach2-deficient animals. Whole-transcriptome profiles of tumors from Bach2-defi- and CD8 + T cells was also apparent from immunohistochemical analysis of tumor sections ( Figure 2D and Supplemental Figure  1A ). Consistent with their increased density, we observed elevated frequencies of proliferating Ki67 + cells among both CD8 + and CD4 + Foxp3 -effector T cells within tumors from Bach2-deficient mice ( Figure 2E ). Moreover, intracellular cytokine staining following brief restimulation of tumor-infiltrating cells ex vivo showed strikingly elevated frequencies of CD4 + and CD8 + T cells expressing the effector cytokine IFN-γ within tumors from Bach2-deficient mice ( Figure 2F and Supplemental Figure 1B) . Thus, BACH2 limits the proliferation of CD8 + and CD4 + effector T cells and their expression of effector cytokines within tumors.
The protein encoded by recombination-activating gene 1 (Rag1) is required for rearrangement of T and B cell receptor loci, and its loss results in a complete defect in generation of mature T and B lymphocytes (19) . To test whether decreased tumor growth in the absence of BACH2 was dependent upon lymphocytes, we measured growth kinetics of subcutaneously implanted B16 melanoma cells in Bach2 Rag1 double-deficient animals ( Figure 2G ). + and CD8 + effector T cells in tumors from Bach2-deficient mice. In particular, we noted elevated expression of genes that are expressed by T cells (including Cd3g, Il2rg, Thy1, and Cd8a) (16) or associated with effector differentiation (including Tbx21 and Prdm1) (17, 18) and function (including Ifng, Gzmb, and Fasl) (ref. 16 and Figure 2A) . We therefore measured infiltration of CD4 + and CD8 + T cells within tumors using flow cytometry. Normalized for differences in tumor mass (Figure 2B ), the density of both CD4 + and CD8 + T cells was higher in tumors from Bach2-deficient animals ( Figure 2C ). Increased density of CD4 DTR mice and administered PBS or DTx in conjunction with α-CD8-and/or α-IFN-γ-depleting monoclonal antibodies or isotype control antibodies (IgG) at indicated time points relative to implantation. Tumor growth was measured at indicated time points after subcutaneous implantation of 2.5 × 10 5 B16 cells. All data are representative of ≥2 independent experiments. Error bars represent mean ± SEM. **P < 0.01; ***P < 0.005; ****P < 0.001, 2-tailed Student's t tests. jci.org Volume 126 Number 2 February 2016 predominantly exerts this function through its role in CD4 + Tregs, thus potently suppressing the antitumor activity of CD8 + T cells. These findings identify a molecular axis of tumor immunosuppression and provide targets for design of immune-based therapies aimed at reversing deleterious immunosuppression in cancer.
Methods
Additional details can be found in the Supplemental Methods. Animals. C57BL/6J and Rag1 -/-(B6.129S7-Rag1 tm1Mom/J ) mice were purchased from The Jackson Laboratory. Bach2-deficient mice, which have been previously described (6), were backcrossed >16 times with C57BL/6 mice.
Data deposition. Data from whole-transcriptome analyses are deposited under GEO accession number GSE74653.
Statistics. Two-tailed Student's t tests were used to calculate statistical significance of the difference in sample means. P values of less than 0.05 were considered significant and are provided.
Study approval. Experiments were approved by the Institutional Animal Care and Use Committee of the National Cancer Institute and performed in accordance with NIH guidelines. Figure 3, A and B) , and near-complete DTx -induced depletion of Foxp3 + Tregs within Foxp3 DTR compartments (Supplemental Figure 3C) . Strikingly, BACH2-mediated tumor immunosuppression was dependent upon Foxp3 + Tregs, since impaired tumor growth and loss of immunosuppression was only observed when DTx was administered to KO:Foxp3 DTR mice ( Figure 3C ). Growth of subcutaneous tumors in reconstituted Rag1 -/-radiation chimeras occurred with distinct kinetics compared with that in WT nonirradiated animals, as is consistent with our previous experience (our unpublished observations), and the duration of measurement in these experiments was limited by systemic effects of Treg depletion in mice reconstituted with mixtures of KO and Foxp3 DTR BM and administered DTx. Collectively, these findings suggest that BACH2-mediated tumor immunosuppression is dependent upon Foxp3 + Tregs. We observed increased frequencies of CD8 + T cells and elevated production of IFN-γ within tumors of Bach2-deficient animals. This led us to ask whether Treg-dependent tumor immunosuppression mediated by BACH2 is caused by suppression of CD8 + T cells or IFN-γ. Strikingly, augmented tumor immunity observed upon administration of DTx to KO:Foxp3 DTR mice was partially reversed upon depletion of CD8 + T cells and fully reversed upon simultaneous depletion of CD8 + T cells and blockade of IFN-γ ( Figure 3D ). Thus, we conclude that BACH2 causes tumor growth through Treg-mediated suppression of CD8 + T cells and concomitant IFN-γ-dependent effector mechanisms.
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In this study, we have found that the TF BACH2 is required for establishment of immunosuppression within tumors. Despite its activity in a diversity of innate and adaptive immune cell types, it
